CG Oncology, Inc. (CGON) Stock

CG Oncology, Inc., an innovative oncolytic immunotherapy firm, specializes in the development and commercialization of advanced therapies aimed at preserving the bladder for patients battling bladder cancer.

The company's pioneering portfolio includes BOND-003, designed for treating high-risk bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. Additionally, CORE-001 combines cretostimogene with pembrolizumab for high-risk BCG-unresponsive NMIBC, while CORE-002 pairs cretostimogene with the checkpoint inhibitor nivolumab for muscle invasive bladder cancer.

Further expanding its therapeutic options, CG Oncology is advancing PIVOT-006, a cretostimogene monotherapy tailored for intermediate-risk NMIBC post-transurethral resection of the bladder tumor, and CORE-008 for high-risk NMIBC patients, including those with prior BCG exposure. Founded in 2010 and headquartered in Irvine, California, CG Oncology, Inc. was formerly known as Cold Genesys, Inc., rebranding itself in June 2020 to better reflect its focus and aspirations in the oncological field.